2020 Komen CSNJ Breast Cancer Conference

Thank you for joining us at the 2020 Breast Cancer Conference!

View Photos



This year’s conference focused on bringing together oncology experts to share their knowledge and approaches to advancing precision medicine in clinical practice – as it is rapidly becoming the most studied form of cancer therapy and the standard of care for patients with advanced breast cancer. The goal is to educate the care team on emerging developments and advancements of diagnostic, prognostic and therapeutic approaches that are advancing precision medicine in breast cancer care.

The conference agenda featured a keynote presentation, lunch presentation, six breakout sessions and networking opportunities.

Jointly Provided by Susan G. Komen Central and South Jersey and American Academy of CME, Inc.



8 am • Registration & Breakfast


8:30 am • Keynote Presentation with Komen Scholar Dr. Antonio Wolff

The Role of Prognostic and Predictive Biomarkers in
Improving the Survivorship Experience of Breast Cancer Patients


9:45 am – 10:45 am • Breakouts

Session 1

Emerging Role of Immune Checkpoint Therapy in Triple-Negative Breast Cancer and the Search for Biomarkers of Response

Dr. Shridar Ganesan, Rutgers Cancer Institute of NJ

Session 2

Overcoming Barriers to Clinical Trial Enrollment for Minority and Other Underrepresented Populations

Jimmy McCann BSN, RN-BC, Oncology Care Program Manager, Regional Cancer Care Associates (RCCA)

Session 3

Determining an Optimal Multimodal Approach to Pain Management for Breast Cancer Patients

Lisa R. Allen, MD, FACS, Director of the Capital Health Center for Comprehensive Breast Care


10:45 am – 11 am • Snack Break


11 am – 12 pm • Breakouts

Session 1

Opportunities for Using Big Data to Advance Breast Cancer Care

Lee S. Schwartzberg, MD, FACP, Medical Director of the West Cancer Center

Session 2

Case-Based Study: The Promise and Limitations of Precision Medicine in Clinical Practice

Dr. Robert Somer, Head, Division of Hematology/Medical Oncology, Director, Clinical Trials Program, MD Anderson Cancer Center at Cooper, Professor of Medicine, Cooper Medical School of Rowan University

Session 3

Opioid Addiction Among Breast Cancer Patients: The Risks and Signs

Panel Discussion featuring Roberta McNeill MD,CHCQM, Medical Director II, Provider Network, Health Services and Network Support, Horizon Blue Cross Blue Shield of New Jersey, Government Programs Division, Christine Barton, MSW, LCSW, Horizon Blue Cross Blue Shield of New Jersey, Clinical Design Liaison, Behavioral Health, Angelo Valente, Executive Director, Partnership for Drug Free NJ, and Alkesh N. Patel, MD, FASAM, Behavioral Health Medical Director, Horizon Blue Cross Blue Shield of New Jersey.


The CME/CE Portion of the Conference Is Supported Through Education Grants from:

Daiichi Sankyo ● Genentech ● Novartis ● Pfizer ● Seattle Genetics


Additional Conference Support Provided By




12 pm • Lunchtime Presentation

(CME/CE credit not available)

A New View of an Old Enemy – How Breast Cancer Treatment Looks in 2020

Dr. Patrick Borgen, Chair, Department of Surgery, Director, Breast Cancer, Maimonides Medical

 Supported By

Exact Sciences


Meet Our Keynote Speaker

Komen Scholar Since 2010
Johns Hopkins University School of Medicine
Baltimore, MD

Antonio C. Wolff, M.D., is Professor of Oncology at Johns Hopkins University and a member of the Johns Hopkins Kimmel Cancer Center. A clinician and researcher, Dr. Wolff’s research interests include new treatment strategies, the development and implementation of prognostic and predictive biomarkers (tissue, blood, and imaging) in clinical practice, and how to improve the survivorship experience of breast cancer patients and their caregivers.

He promotes the implementation of research findings in clinical practice, survivorship, and quality of care for breast cancer patients. Dr. Wolff is the Chief Operating Officer of the Translational Breast Cancer Research Consortium (TBCRC)—a research group funded by Komen and that convenes a multidisciplinary group of researchers who plan and conduct studies to better understand breast cancer biology and test new therapies. He is also an Associate Editor of the Journal of Clinical Oncology and Chair of the NCI ECOG-ACRIN Breast Cancer Committee. Dr. Wolff’s Komen funding supports the development of a tissue and bodily fluid repository that has patient samples linked to clinical data and surveys that can be used to answer critical research questions.

Meet Our Presenters

Shridar Ganesan, MD, PhD

Learn More

Jimmy McCann BSN, RN-BC

Learn More

Lisa R. Allen, MD, FACS

Learn More

Lee S. Schwartzberg, MD, FACP

Learn More

Robert A. Somer, MD

Learn More

Roberta McNeill, MD

Learn More

Christine Barton, MSW, LCSW

Learn More

Angelo Valente

Learn More

Alkesh N. Patel MD, FASAM

Learn More

Patrick Borgen, MD

Learn More

Accreditation and CME/CE Credit Information

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. American Academy of CME, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


American Academy of CME, Inc., designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Nurses

American Academy of CME, Inc., designates this educational activity for 3.0 ANCC contact hours (pharmacotherapeutic contact hours pending).

Physician Assistants

Per the AAPA, PAs attending an educational activity that has been designated for AMA PRA Category 1 Credit™ may claim up to the maximum number of credits designated.

Other Team Members

Other members of the breast cancer care team will receive a certificate of participation.

Go to Top